

Enantioselective Synthesis of Cyclohexenol Derivatives from γ -Aryl-substituted Enals via an Organocatalyzed Three-Component Reaction

Debashis Majee, Satish Jakkampudi, Hadi D. Arman, and John C.-G. Zhao*

Department of Chemistry, University of Texas at San Antonio

Supporting Information

Table of Contents


General Information	S-1
Catalyst Preparation.....	S-2
Detailed Experimental Procedures.....	S-3
Detailed Catalyst Screening and Condition Optimizations	S-5
ORTEP drawing of compound 4a	S-7
Alternative Reaction Mechanism	S-8
Compound Characterization Data	S-9
Additional References.....	S-21
Copy of ^1H and ^{13}C NMR Spectra	S-22
Copy of HPLC Chromatograms.....	S-41

General Information

All reactions were carried out in closed vial and monitored by TLC and the products were visualized by UV detection. Flash column chromatography was performed with silica gel (32-63 μ). ^1H and ^{13}C NMR spectra were recorded on a 500 MHz (125 MHz for ^{13}C NMR) or a 300 MHz spectrometer (75 MHz for ^{13}C NMR). The following abbreviations were used to designate chemical shift multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. All first-order splitting patterns were assigned on the basis of the appearance of the multiplet. Splitting patterns that could not be easily interpreted are designated as multiplet (m) or broad (br). FTIR spectra were measured on a Bruker Vector 22 instrument. Enantiomeric excesses (ee) were determined by HPLC analysis using a Shimadzu instrument with chiral HPLC columns. ChiralPak IB, IC, and ID columns (4.6 mm \times 250 mm) were purchased from Daicel Chemical Industries. Melting points were recorded on MEL-TEMP melting point apparatus in open capillaries and uncorrected. HRMS analyses were conducted at the RCMI Proteomics and Protein Biomarkers Core Facility of the Department of Chemistry, UTSA.

Materials: All the α,β -unsaturated aldehydes were prepared by following the literature procedure.¹² All the nitroalkenes were either purchased from commercial sources or synthesized by following known literature procedures.¹³ All catalysts, except for **5e**, **5f**, **5g**, and **5y**, are known compounds and were prepared by following the known procedures.¹⁴ Tetrahydrofuran was dried over sodium metal under argon atmosphere and distilled before prior to use.

Catalyst Preparation



Scheme S-1. Synthesis of the squaramide catalysts **5**.

Preparation of intermediate c: Intermediate **c** was prepared according to the literature procedure.¹⁵ In a 250-mL round-bottom flask, the Boc-protected amino acid **b** (5.0 mmol), hydroxybenzotriazole (HOBT, 676 mg, 5.0 mmol, 1.0 equiv.), and EDC hydrochloride (959 mg, 5.0 mmol, 1.0 equiv.) were suspended in dry CH₂Cl₂ (35 mL) at room temperature. After 2 min., DIPEA (1.3 g, 10 mmol, 2.0 equiv.) was added, which was followed immediately by the benzylamine derivative **a** (5.0 mmol, 1.0 equiv.). The reaction mixture was allowed to stir further for 2 h at the same temperature. During the reaction progress, due to the consumption of HOBT, the mixture changed from turbid to a clear solution. The reaction was then quenched by adding 1N HCl (20 mL) and the mixture was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting colorless liquid was further dissolved in CH₂Cl₂ (25 mL) and treated with trifluoroacetic acid (75 mmol, 15 equiv.) under stirring. After 1 h the reaction mixture was diluted with CH₂Cl₂ (30 mL) and quenched with chilled saturated solution of sodium carbonate (50 mL). After neutralization by adding more saturated sodium carbonate solution, the aqueous layer was extracted with CH₂Cl₂ (3 × 20 mL), and the combined organic layers were dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give a white solid that was used without further purification.

Synthesis of intermediate d: The crude intermediate **c** (5.0 mmol) was dissolved in CH₂Cl₂ (25 mL) and dimethylsquarate (710.6 mg, 5.0 mmol) was added portion wise over 10 min. at room temperature. The mixture was further stirred for 72 h to complete the reaction (monitored by TLC). The solvent was then removed under reduced pressure and the crude product was purified by in flash column chromatography using 98:2 CH₂Cl₂/MeOH as the eluent to give the intermediate **d** (63-72%).

Synthesis of 5: In an oven-dried round-bottom flask, the quinine- or quinidine-derived 9-amino(9-deoxy)cinchona alkaloid (255.5 mg, 0.79 mmol) was dissolved in dry methanol (10 mL) at room temperature. To that solution, **d** (0.79 mmol) was added in one portion and the mixture was further stirred for 48-90 h. During the progress, a white precipitate was observed. The precipitate was filtered and washed with cold MeOH/hexane (1:4), which gave the pure catalyst **5**. The filtrate was further concentrated and purified by silica gel flash column chromatography using MeOH/CH₂Cl₂ (0:100 to 5:95) as a mobile phase to give an additional portion of the catalyst. Both the portions were combined for catalytic use (total yield 55-60%).

Detailed Experimental Procedures

General procedure for the three-component reaction: To a stirred solution of the appropriate nitroalkene (0.60 mmol, 3.0 equiv.) and the squaramide catalyst **5f** (24.9 mg, 0.040 mmol, 20 mol %) in freshly distilled THF (0.7 mL) at room temperature, the γ -aryl- α,β -unsaturated aldehyde (0.20 mmol) was added. The mixture was further stirred at room temperature for 72 h (the progress of the reaction was monitored by TLC). After the completion of the reaction, the solvent was evaporated in a rotary evaporator under the reduced pressure and the crude product obtained was purified by flash column chromatography using 90:10 to 95:5 hexane/EtOAc as an eluent.

1.0 mmol-scale reaction

To a stirred solution of *trans*- β -nitrostyrene (**2a**, 447.5 mg, 3.0 mmol, 3.0 equiv.) and the squaramide catalyst **5f** (124.4 mg, 0.20 mmol, 0.2 equiv) in freshly distilled THF (3.5 mL) at room temperature, 4-phenyl-2-butenal (**1a**, 146.2 mg, 1.0 mmol) was added. The mixture was further stirred at room temperature for 72 h (the progress of the reaction was monitored by TLC). After the completion of the reaction, the solvent was evaporated in a rotary evaporator under reduced pressure and the crude product obtained was purified by flash column chromatography using 95:5 hexanes/EtOAc as an eluent to give **4a** as white color solid (310.5 mg, 70% yield, 87:13 dr, 99% ee).

Acetylation of the adduct **4a**

To a solution of the adduct **4a** (44.5 mg, 0.10 mmol) in CH₂Cl₂ (3.0 mL), acetic anhydride (0.10 mL, 1.0 mmol) and DMAP (2.5 mg, 0.020 mmol) were added at 0 °C and the reaction mixture was further stirred for 30 min at room temperature. After the completion the reaction, the solvent was evaporated under reduced pressure, and the crude product was purified by flash chromatography using 93:7 hexanes/EtOAc as an eluent to give **6** as white solid (38.7 mg, 80% yield).

Oxidation of the adduct **4a**

To a solution of the adduct **4a** (44.5 mg, 0.10 mmol) in CH₂Cl₂ (3.0 mL), 100 mg Celite was suspended and then PCC (64.7 mg, 0.30 mmol) were added at room temperature and the reaction mixture was further stirred for 12 h at the same temperature. After the completion the reaction, the mixture was filtered through a Celite pad and the crude product was purified by flash chromatography using 92:8 hexane/EtOAc as an eluent to give **7** as white solid. (37.6 mg, 85% yield).

Detailed Catalyst Screening and Condition Optimizations




Figure S-1. Structure of catalyst used in the screening

Table S-1: Screening of the catalysts^a

	1a	2a		4a
Entry	Catalyst	Yield (%) ^b	dr (%) ^c	ee (%) ^d
1	5a	41	60:40	53
2	5h	42	59:41	56
3	5i	60	61:39	58
4	5j	28	61:39	79
5	5k	0	-	-
6	5l	32	50:50	54
7	5b	53	65:35	64 ^e
8	5m	47	64:36	56 ^e
9	5n	37	66:34	70 ^e
10	5o	49	70:30	83 ^e
11	5p	55	80:20	90 ^e
12	5q	35	59:41	62 ^e
13	5r	23	61:39	61 ^e
14	5c	0	-	-
15	5s	0	-	-
16	5t	56	77:23	89
17	5u	49	80:20	94 ^e
18	5d	51	79:21	95
19	5v	48	85:15	96 ^e
20	5w	0	-	-
21	5x	0	-	-
22	5e	34	70:30	97
23	5f	80	88:12	99
24	5g	75	81:19	97 ^e
25	5y	67	79:21	96
26 ^f	5f	34	87:13	99

^aUnless otherwise noted, all reactions were carried out with **1a** (0.20 mmol) and **2a** (0.6 mmol) in dry THF (0.7 mL) at room temperature for 72 h, using **5** (20 mol %) as the catalyst. ^bYield of the isolated product. ^cDiastereomeric ratio was determined by ¹H NMR analysis of the crude reaction mixture. ^dDetermined by chiral HPLC analysis. ^eThe opposite enantiomer was obtained as the major product. ^fThe catalyst loading was 10 mol %.






Figure S-2. ORTEP drawing of compound 4a



Scheme S-2. Alternative reaction mechanism for the three-component reaction

Compound Characterization Data


3-[(*S*)-*N'*-[3,5-Bis(trifluoromethyl)benzyl]-3,3-dimethylbutanamid-2-ylamino]-4-[[(*9R*)-6'-methoxycinchonan-9-yl]amino]-3-cyclobutene-1,2-dione (**5e**)



The crude product was purified by silica gel flash column chromatography using MeOH/CH₂Cl₂ (0:100 to 5:95) to get **5e** as a white solid, 2.01 g, 55% yield, m.p. 178-180 °C; ¹H NMR (500 MHz, CDCl₃) δ: 8.88 (s, 2H), 8.56 (s, 2H), 8.06 (d, *J* = 9.2 Hz, 1H), 7.95 (s, 1H), 7.70 (s, 1H), 7.44-7.40 (m, 2H), 7.27 (s, 1H), 7.12 (br, 1H), 6.51 (br,

1H), 5.97 (d, *J* = 14.3 Hz, 1H), 5.29 (d, *J* = 16.9 Hz, 1H), 5.13 (d, *J* = 10.0 Hz, 1H), 4.47 (s, 2H), 4.14 (br, 1H), 3.89 (s, 3H), 3.42 (br, 2H), 3.06 (s, 3H), 2.41 (s, 1H), 1.92 (s, 3H), 1.72 (s, 3H), 1.16-1.04 (m, 2H), 0.85 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ: 183.0, 181.7, 171.8, 169.2, 165.5, 159.0, 148.1, 145.2, 144.7, 141.0, 140.8, 132.2, 132.1 (q, *J*_{C-F} = 33.7 Hz), 125.8, 125.3 (q, *J*_{C-F} = 273.0 Hz), 122.7, 121.0, 119.8 (br.), 119.5, 115.1, 101.9, 64.8, 59.3, 56.0, 53.6, 49.5, 47.1, 42.1, 39.7, 35.6, 28.1, 27.4, 26.5, 26.1. *v*_{max} (neat, cm⁻¹): 3234, 2936, 1660, 1622, 1582, 1509, 1434, 1379, 1349, 1275, 1243, 1170, 1128, 1021. HRMS (ESI) *m/z* calcd for C₃₉H₄₂F₆N₅O₄⁺ ([*M*+*H*]): 758.3136; found: 758.3146.

3-[(*S*)-*N'*-Benzyl-3,3-dimethylbutanamid-2-ylamino]-4-[[(*9R*)-6'-methoxycinchonan-9-yl]amino]-3-cyclobutene-1,2-dione (**5f**)




The crude product was purified by silica gel flash column chromatography using MeOH/CH₂Cl₂ (0:100 to 3:97) to get **5f** as a white solid, 1.86 g, 60% yield, m.p. 190-192 °C; ¹H NMR (500 MHz, CDCl₃) δ: 8.70 (br, 1H), 8.54-8.62 (m, 1H), 8.42 (br, 1H), 8.05 (d, *J* = 9.1 Hz, 1H), 7.98 (s, 1H), 7.81 (s, 1H), 7.43 (d, *J* = 9.3 Hz, 1H), 7.26 (br, 1H), 7.08-

7.06 (m, 3H), 6.84-6.83 (m, 2H), 6.51 (br, 1H), 5.90 (ddd, *J*₁ = 17.0 Hz, *J*₂ = 10.5, *J*₃ = 6.2 Hz, 1H), 5.20 (d, *J* = 17.1 Hz, 1H), 5.05 (d, *J* = 10.3 Hz, 1H), 4.54 (d, *J* = 9.5 Hz, 1H), 4.13 (s, 2H), 3.92 (s, 3H), 3.78-3.75 (m, 1H), 3.36 (s, 1H), 3.24 (s, 1H), 2.97-2.93 (m, 2H), 2.30-2.28 (m, 2H), 1.64-1.57 (m, 3H), 1.11 (s, 1H), 0.99 (s, 1H), 0.81 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ: 183.0,

182.1, 170.8, 168.9, 166.1, 158.8, 148.2, 145.1, 140.8, 137.7, 132.0, 128.8, 128.4, 127.6, 122.7, 119.9, 115.1, 101.9, 64.9, 59.3, 56.1, 53.3, 49.4, 47.2, 43.4, 39.8, 35.9, 28.2, 27.3, 26.7, 25.8, 23.0, 14.5, 12.4 ν_{\max} (neat, cm^{-1}): 3301, 2932, 1795, 1652, 1621, 1582, 1509, 1432, 1368, 1227, 1128. HRMS (ESI) m/z calcd for $\text{C}_{37}\text{H}_{44}\text{N}_5\text{O}_4$ ($[\text{M}+\text{H}]^+$): 622.3388; found: 622.3390.


3-[(*S*)-*N'*-Benzyl-3,3-dimethylbutanamid-2-ylamino]-4-[[*(8\alpha,9S)*-6'-methoxycinchonan-9-yl]amino]-3-cyclobutene-1,2-dione (5g**)**



The crude product was purified by silica gel flash column chromatography using $\text{MeOH}/\text{CH}_2\text{Cl}_2$ (0:100 to 4:96) to get **5g** as a white solid, 1.71 g, 55% yield, m.p. 182-184°C; ^1H NMR (500 MHz, CDCl_3) δ : 8.45 (br, 1H), 8.01-7.98 (m, 3H), 7.57 (s, 2H), 7.38-7.36 (m, 1H), 7.02-6.94 (m, 4H), 6.28 (br, 1H), 5.89 (br, 1H), 5.03-4.93 (m, 2H),

4.58 (s, 1H), 3.94-3.88 (m, 5H), 3.40 (s, 1H), 3.24 (t, $J = 10$ Hz, 1H), 2.85-2.76 (m, 2H), 2.29 (d, $J = 7.2$ Hz, 1H), 1.64-1.44 (m, 4H), 0.88 (br, 9H). ^{13}C NMR (125 MHz, CDCl_3) δ : 183.3, 170.8, 168.8, 167.2, 159.0, 148.2, 145.1, 144.8, 142.1, 137.9, 132.2, 129.4, 128.7, 127.6, 122.6, 120.0, 114.9, 102.0, 64.9, 56.2, 53.9, 43.5, 41.2, 40.1, 35.4, 28.3, 26.5. ν_{\max} (neat, cm^{-1}): 33264, 2942, 1657, 1621, 1581, 1524, 1454, 1367, 1259, 1228, 1176, 1132, 1028. HRMS (ESI) m/z calcd for $\text{C}_{37}\text{H}_{44}\text{N}_5\text{O}_4$ ($[\text{M}+\text{H}]^+$): 622.3388; found: 622.3401.

3-[(*S*)-*N'*-Benzyl-3-methylbutanamid-2-ylamino]-4-[[*(9R)*-6'-methoxycinchonan-9-yl]amino]-3-cyclobutene-1,2-dione (5y**)**




The crude product was purified by silica gel flash column chromatography using $\text{MeOH}/\text{CH}_2\text{Cl}_2$ (0:100 to 4:96) to get **5y** as a white solid, 1.67 g, 58% yield, m.p. 170-172 °C; ^1H NMR (500 MHz, CDCl_3) δ : 8.75 (br, 2H), 8.50 (s, 1H), 8.09-8.04 (m, 2H), 7.81 (s, 1H), 7.46 (d, $J = 9.3$ Hz, 2H), 7.11 (s, 3H), 6.88 (s, 2H), 6.54 (s, 1H), 5.93 (td, $J_1 = 11.0$ Hz, $J_2 =$

10.3 Hz, $J_3 = 5.7$ Hz, 1H), 5.25 (d, $J = 17.2$ Hz, 1H), 5.09 (d, $J = 10.4$ Hz, 1H), 4.60 (s, 1H), 4.10-3.94 (m, 6H), 3.72 (s, 1H), 3.35 (s, 1H), 3.22 (s, 1H), 3.03-3.00 (m, 2H), 2.33 (d, $J = 8.1$ Hz, 1H), 1.94-1.86 (m, 2H), 1.67-1.62 (m, 3H), 1.14 (s, 1H), 1.07-0.89 (m, 2H), 0.81 (d, $J = 6.4$ Hz, 3H),

0.73 (d, $J = 5$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ : 183.2, 181.55, 171.7, 169.2, 165.6, 158.7, 148.2, 145.3, 145.1, 140.9, 137.6, 132.0, 128.8, 128.3, 127.6, 127.4, 122.8, 119.9, 115.0, 101.9, 63.0, 59.2, 56.0, 53.4, 49.4, 47.1, 43.2, 39.8, 33.3, 28.2, 27.3, 25.8, 18.9, 18.7, 12.3. ν_{max} (neat, cm^{-1}): 3232, 2933, 1655, 1621, 1509, 1452, 1367, 1260, 1241, 1228, 1159, 1080, 1027. HRMS (ESI) m/z calcd for $\text{C}_{36}\text{H}_{42}\text{N}_5\text{O}_4^+$ ($[\text{M}+\text{H}]$): 608.3231; found: 608.3249.


(1'*R*,2'*S*,3'*S*,4'*S*)-3'-Nitro-5'-[(*R*)-2-nitro-1-phenylethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4a)



The crude material was purified by flash column chromatography using hexanes/EtOAc (95:5) as an eluent to get **4a** as a white solid, 71 mg, 80% yield, m.p. 140-142 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.46-7.31 (m, 5H), 7.21-7.19 (m, 1H), 7.17-7.09 (m, 3H), 7.05 (t, $J = 7.4$ Hz, 2H), 6.61-6.55 (m, 4H), 6.02 (d, $J = 4.2$ Hz, 1H), 5.24 (dd, $J_1 = 12.3$ Hz, $J_2 = 9.7$ Hz, 1H), 5.11 (dd, $J_1 = 12.0$ Hz, $J_2 = 8.5$ Hz, 1H), 4.95 (dd, $J_1 = 12.2$ Hz, $J_2 = 6.9$ Hz, 1H), 4.80 (t, $J = 8.0$ Hz, 1H), 4.63 (dd, $J_1 = 9.6$ Hz, $J_2 = 7.0$ Hz, 1H), 3.79-3.76 (m, 2H), 2.63 (d, $J = 7.5$ Hz, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ : 137.23, 137.0, 136.5, 136.2, 130.8, 130.2, 129.6, 128.5, 128.1, 128.0, 79.0, 73.4, 49.0, 48.7, 47.8. ν_{max} (neat, cm^{-1}): 3586, 3029, 1550, 1453, 1433, 1378, 1246, 1060, 1033, 970. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{24}\text{N}_2\text{NaO}_5$ ($[\text{M}+\text{Na}]^+$): 467.1577; found: 467.1573. Enantiomeric excess of **4a** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 220$ nm), minor enantiomer: $t_R = 18.0$ min, major enantiomer: $t_R = 50.0$ min.

(1'*R*,2'*S*,3'*S*,4'*S*)-4''-Methyl-3'-nitro-5'-[(*R*)-2-nitro-1-(*p*-tolyl)ethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4b)


The crude material was purified by flash column chromatography using hexanes/EtOAc (93:7) as an eluent to get **4b** as a white solid, 68.9 mg, 73% yield, m.p. 130-132 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.29-7.24 (m, 3H), 7.23-7.19 (m, 4H), 7.17-7.14 (m, 2H), 6.85 (d, $J = 7.7$ Hz, 3H), 6.63 (d, $J = 7.4$ Hz, 2H), 6.44 (br, 2H), 6.00 (d, $J = 3.4$ Hz, 1H), 5.21 (dd, $J_1 = 12.2$ Hz, $J_2 = 9.7$ Hz, 1H), 5.08 (dd, $J_1 = 12.6$ Hz, $J_2 = 8.5$ Hz, 1H), 4.91 (dd, $J_1 = 12.3$ Hz, $J_2 = 7.0$ Hz, 1H), 4.79 (t, $J = 8.1$ Hz, 1H), 4.59 (d, $J = 7.3$ Hz, 1H), 3.80-3.65 (m, 2H), 2.55 (d, $J = 7.6$ Hz, 1H), 2.36 (s, 3H),



2.21 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ : 138.3, 137.6, 137.1, 136.7, 134.2, 133.1, 130.7, 130.3, 130.3, 129.1, 128.4, 128.4, 127.9, 127.9, 90.8, 79.1, 73.5, 48.7, 47.6, 21.4, 21.4. ν_{max} (neat, cm^{-1}): 3542, 2922, 1548, 1514, 1452, 1374, 1265, 1050, 976, 899. HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{27}\text{N}_2\text{O}_5$ ($[\text{M}-\text{H}]^-$): 471.1925; found: 471.1938. Enantiomeric excess of **4b** was determined by chiral stationary phase HPLC analysis using a ChiralPak IB column (90:10 hexanes/*i*-PrOH

at 1.0 mL/min, $\lambda = 220$ nm), minor enantiomer: $t_R = 21.1$ min, major enantiomer: $t_R = 22.9$ min.


(1'R,2'S,3'S,4'S)-4''-Fluoro-5'-[(R)-1-(4-fluorophenyl)-2-nitroethyl]-3'-nitro-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4c**)**



The crude material was purified by flash column chromatography using hexanes/EtOAc (91:9) as an eluent to get **4c** as a white solid, 67.2 mg, 70% yield, m.p. 134-136 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.36-7.33 (m, 2H), 7.24-7.21 (m, 1H), 7.18-7.15 (m, 2H), 7.08-7.05 (m, 2H), 6.76 (t, $J = 8.5$ Hz, 2H), 6.64-6.57 (m, 3H), 6.52 (br, 2H), 5.98 (d, $J = 3.3$ Hz, 1H), 5.18 (dd, $J_1 = 12.4$ Hz, $J_2 = 9.5$ Hz, 1H), 5.09-5.02 (m, 1H), 4.91 (dd, $J_1 = 12.3$ Hz, $J_2 = 7.1$ Hz, 1H), 4.78 (t, $J = 7.4$ Hz, 1H), 4.62


(dd, $J_1 = 9.3$, $J_2 = 7.2$ Hz, 1H), 3.77-3.73 (m, 2H), 2.81 (d, $J = 7.3$ Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ : 162.7 (d, $J_{\text{C-F}} = 239.4$ Hz), 162.5 (d, $J_{\text{C-F}} = 239.4$ Hz), 137.0, 136.3, 133.0, 131.9, 130.7, 130.2, 130.1 (d, $J_{\text{C-F}} = 7.5$ Hz), 129.8 (d, $J_{\text{C-F}} = 7.5$ Hz), 128.7, 128.2, 116.5 (d, $J_{\text{C-F}} = 21.3$ Hz), 115.4 (d, $J_{\text{C-F}} = 21.3$ Hz), 90.7, 79.0, 73.1, 48.6, 48.0, 47.1. ν_{max} (neat, cm^{-1}): 3526, 2922, 1603, 1548, 1507, 1452, 1347, 1224, 1160, 1050. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{21}\text{F}_2\text{N}_2\text{O}_5$ ($[\text{M}-\text{H}]^-$): 479.1424; found: 479.1430. Enantiomeric excess of **4c** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 220$ nm), minor enantiomer: $t_R = 10.3$ min, major enantiomer: $t_R = 31.8$ min.

(1'R,2'S,3'S,4'S)-4''-Chloro-5'-[(R)-1-(4-chlorophenyl)-2-nitroethyl]-3'-nitro-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4d**)**



The crude material was purified by flash column chromatography using hexanes/EtOAc (92:8) as an eluent to get **4d** as a white solid, 71.8 mg, 70% yield, m.p. 140-142 °C; ¹H NMR (500 MHz, CDCl₃) δ: 7.37-7.34 (m, 3H), 7.31-7.29 (m, 2H), 7.23-7.20 (m, 2H), 7.19-7.16 (m, 2H), 7.05 (d, *J* = 8.2 Hz, 2H), 6.60 (d, *J* = 7.5 Hz, 2H), 6.49 (br, 2H), 5.97 (d, *J* = 3.2 Hz, 1H), 5.15 (dd, *J*₁ = 12.5 Hz, *J*₂ = 9.2 Hz, 1H), 5.06 (dd, *J*₁ = 12.1 Hz, *J*₂ = 8.3 Hz, 1H), 4.92-4.88 (m, 2H), 4.76 (t, *J* = 7.6 Hz, 1H), 4.61 (dd, *J*₁ = 9.1 Hz, *J*₂ = 7.3 Hz, 1H), 3.79-3.69 (m, 2H), 2.92 (d, *J* = 7.1 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ: 136.8, 136.1, 135.8, 134.6, 134.3, 134.0, 130.7, 130.2, 129.8, 129.7, 129.5, 128.7, 128.2, 90.5, 78.7, 73.0, 48.4, 47.9, 47.2. *v*_{max} (neat, cm⁻¹): 3501, 2918, 1548, 1490, 1452, 1373, 1091, 1051, 1013, 972. HRMS (ESI) *m/z* calcd for C₂₆H₂₁Cl₂N₂O₅ ([M-H]⁻): 511.0833; found: 511.0830. Enantiomeric excess of **4d** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: *t*_R = 11.0 min, major enantiomer: *t*_R = 32.5 min.


(1'*R*,2'*S*,3'*S*,4'*S*)-4''-Bromo-5'-[(*R*)-1-(4-bromophenyl)-2-nitroethyl]-3'-nitro-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4e**)**



The crude material was purified by flash column chromatography using hexanes/EtOAc (91:9) as an eluent to get **4e** as a light green solid, 90.3 mg, 75% yield, m.p. 150-152 °C; ¹H NMR (500 MHz, CDCl₃) δ: 7.51 (d, *J* = 8.4 Hz, 2H), 7.26-7.16 (m, 9H), 6.60 (d, *J* = 7.2 Hz, 2H), 6.43 (br, 2H), 5.98 (d, *J* = 3.5 Hz, 1H), 5.16 (dd, *J*₁ = 12.5 Hz, *J*₂ = 9.3 Hz, 1H), 5.05 (dd, *J*₁ = 12.6 Hz, *J*₂ = 8.4 Hz, 1H), 4.90 (dd, *J*₁ = 12.5 Hz, *J*₂ = 7.2 Hz, 1H), 4.76 (t, *J* = 7.6 Hz, 1H), 4.63-4.56 (m, 1H), 3.80-3.67 (m, 2H), 2.75 (d, *J* = 7.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ: 136.7, 136.3, 136.0, 135.1, 132.7, 131.7, 130.8, 130.2, 129.8, 128.8, 128.3, 122.5, 122.2, 90.4, 78.6, 73.1, 48.3, 48.1, 47.3. *v*_{max} (neat, cm⁻¹): 3500, 2918, 1547, 1487, 1452, 1432, 1373, 1099, 1073, 1009, 904. HRMS (ESI) *m/z* calcd for C₂₆H₂₁Br₂N₂O₅ ([M-H]⁻): 598.9823; found: 598.9813. Enantiomeric excess of **4e** was determined by chiral stationary phase HPLC analysis using a

ChiralPak IC column (92.5:7.5 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 15.1 min, major enantiomer: t_R = 53.3 min.


(1'*R*,2'*S*,3'*S*,4'*S*)-2''-Bromo-5'-[(*S*)-1-(2-bromophenyl)-2-nitroethyl]-3'-nitro-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4f)



The crude material was purified by flash column chromatography using hexanes/EtOAc (93:7) as an eluent to get **4f** as a brown solid, 78.3 mg, 65% yield, m.p. 125-127 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.66 (d, J = 6.7 Hz, 1H), 7.56 (dd, J_1 = 7.9 Hz, J_2 = 1.3 Hz, 1H), 7.43-7.41 (m, 1H), 7.25-7.23 (m, 1H), 7.16 (t, J = 7.6 Hz, 2H), 7.11 (t, J = 7.1 Hz, 2H), 6.98 (td, J_1 = 7.7 Hz, J_2 = 1.6 Hz, 1H), 6.79 (td, J_1 = 7.6 Hz, J_2 = 1.3 Hz, 1H), 6.61-6.68 (m, 2H), 6.04 (dd, J_1 = 7.9 Hz, J_2 = 1.6 Hz, 1H), 5.93 (d, J = 3.7 Hz, 1H), 5.20-5.13 (m, 3H), 4.99-4.94 (m, 1H), 4.76 (dd, J_1 = 8.5 Hz, J_2 = 6.9 Hz, 1H), 4.36 (dd, J_1 = 12.9 Hz, J_2 = 6.1 Hz, 1H), 4.03 (t, J = 4.9 Hz, 1H), 2.90 (d, J = 7.1 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ : 136.7, 135.9, 135.3, 134.7, 134.5, 133.4, 132.1, 129.9, 129.9, 129.3, 128.5, 128.4, 128.3, 128.3, 128.0, 127.2, 125.8, 125.0, 90.2, 77.8, 73.1, 47.4, 45.9, 45.1. ν_{max} (neat, cm^{-1}): 3503, 2919, 2850, 1548, 1489, 1471, 1452, 1373, 1263, 1062, 1021, 973. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{21}\text{Br}_2\text{N}_2\text{O}_5$ ($[\text{M}-\text{H}]^-$): 598.9823; found: 598.9822. Enantiomeric excess of **4f** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 19.6 min, major enantiomer: t_R = 40.4 min.


(1'*R*,2'*S*,3'*S*,4'*S*)-3''-Bromo-5'-[(*R*)-1-(3-bromophenyl)-2-nitroethyl]-3'-nitro-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4g)

The crude material was purified by flash column chromatography using hexanes/EtOAc (95:5) as an eluent to get **4g** as a light green solid, 86.7 mg, 68% yield, m.p. 125-127 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.52 (s, 1H), 7.48-7.45 (m, 2H), 7.33-7.18 (m, 8H), 6.91 (t, J = 7.9 Hz, 1H), 6.80 (br, 1H), 6.61 (d, J = 6.8 Hz, 2H), 6.41 (br, 1H), 6.00 (d, J = 4.1 Hz, 1H), 5.15 (dd, J_1 = 12.6 Hz,




$J_2 = 9.4$ Hz, 1H), 5.06 (dd, $J_1 = 12.3$ Hz, $J_2 = 8.4$ Hz, 1H), 4.93-4.87 (m, 1H), 4.77 (t, $J = 10.0$ Hz, 1H), 4.60 (dd, $J_1 = 9.5$ Hz, $J_2 = 6.9$ Hz, 1H), 3.80-3.73 (m, 2H), 2.81 (d, $J = 7.1$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ : 139.6, 138.4, 136.6, 136.0, 132.0, 131.6, 131.3, 131.2, 131.1, 130.8, 130.2, 130.1, 129.9, 128.7, 128.3, 126.7, 123.6, 122.5, 90.2, 78.6, 73.1, 48.4, 48.1, 47.3. ν_{max} (neat, cm^{-1}): 3501, 2921, 2851, 1594, 1547, 1489, 1474, 1452, 1373, 1260, 1199, 996. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{21}\text{Br}_2\text{N}_2\text{O}_5$ ($[\text{M}-\text{H}]^-$): 598.9823; found: 598.9833. Enantiomeric excess of **4g** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (95:5 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 220$ nm), minor enantiomer: $t_R = 32.3$ min, major enantiomer: $t_R = 85.3$ min.

(1R,2R,3S,4S)-3-Nitro-5-[(R)-2-nitro-1-(thiophen-2-yl)ethyl]-2-(thiophen-2-yl)-1,2,3,4-tetrahydro-[1,1'-biphenyl]-4-ol (4h)




The crude material was purified by flash column chromatography using hexanes/EtOAc (90:10) as an eluent to get **4h** as a white solid, 62.1 mg, 68% yield, m.p. 140-142 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.30-7.28 (m, 1H), 7.25-7.17 (m, 3H), 7.08-6.98 (m, 3H), 6.75 (d, $J = 6.7$ Hz, 2H), 6.69-6.68 (m, 1H), 6.10 (d, $J = 3.5$ Hz, 1H), 6.05 (d, $J = 4.6$ Hz, 1H), 5.19 (dd, $J_1 = 12.2$ Hz, $J_2 = 9.1$ Hz, 1H), 5.05 (dd, $J_1 = 12.6$ Hz, $J_2 = 8.5$ Hz, 1H), 4.96 (dd, $J_1 = 12.2$ Hz, $J_2 = 6.9$ Hz, 1H), 4.92-4.89 (m, 2H), 4.08 (dd, $J_1 = 12.7$ Hz, $J_2 = 6.1$ Hz, 1H), 3.86 (t, $J = 5.4$ Hz, 1H), 2.74 (d, $J = 7.3$ Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ : 139.9, 138.1, 136.6, 136.6, 130.9, 130.1, 129.9, 128.7, 128.6, 128.2, 127.8, 127.0, 127.0, 126.3, 126.1, 125.9, 124.9, 91.5, 79.5, 72.8, 48.9, 44.3, 42.9. ν_{max} (neat, cm^{-1}): 3581, 2918, 2849, 1550, 1490, 1430, 1379, 1330, 1246, 1201, 1049, 967. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{19}\text{N}_2\text{O}_5\text{S}_2$ ($[\text{M}-\text{H}]^-$): 455.0741; found: 455.0750. Enantiomeric excess of **4h** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, $\lambda = 220$ nm), minor enantiomer: $t_R = 19.4$ min, major enantiomer: $t_R = 46.2$ min.

(1'*R*,2'*S*,3'*S*,4'*S*)-4-Methoxy-3'-nitro-5'-[(*R*)-2-nitro-1-phenylethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4i)



The crude material was purified by flash column chromatography using hexanes/EtOAc (90:10) as an eluent to get **4i** as a white solid, 64.5 mg, 68% yield, m.p. 120-122 °C; ¹H NMR (500 MHz, CDCl₃) δ: 7.48-7.33 (m, 5H), 7.15-7.06 (m, 3H), 6.68 (d, *J* = 8.8 Hz, 2H), 6.59 (br, 2H), 6.50 (d, *J* = 8.2 Hz, 2H), 6.01 (d, *J* = 3.2 Hz, 1H), 5.25 (dd, *J*₁ = 12.2 Hz, *J*₂ = 9.8 Hz, 1H), 5.08 (dd, *J*₁ = 12.0 Hz, *J*₂ = 8.5 Hz, 1H), 4.94 (dd, *J*₁ = 12.2 Hz, *J*₂ = 6.8 Hz, 1H), 4.79-4.76 (m, 1H), 4.61 (dd, *J*₁ = 9.7 Hz, *J*₂ = 6.9 Hz, 1H), 3.76 (s, 3H), 3.73-3.70 (m, 2H), 2.62 (d, *J* = 7.5 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ: 159.4, 137.3, 136.6, 136.4, 131.3, 131.3, 129.6, 128.5, 128.5, 128.4, 128.0, 127.9, 113.8, 90.7, 79.1, 77.6, 73.4, 55.6, 49.1, 47.9. *v*_{max} (neat, cm⁻¹): 3501, 2920, 2850, 1606, 1547, 1508, 1495, 1454, 1374, 1333, 1247, 1176, 1112, 1030. HRMS (ESI) *m/z* calcd for C₂₇H₂₅N₂O₆ ([M-H]⁻): 473.1718; found: 473.1720. Enantiomeric excess of **4i** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: *t*_R = 23.4 min, major enantiomer: *t*_R = 71.7 min.


(1'*R*,2'*S*,3'*S*,4'*S*)-4-Fluoro-3'-nitro-5'-[(*R*)-2-nitro-1-phenylethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4j)



The crude material was purified by flash column chromatography using hexanes/EtOAc (95:5) as an eluent to get **4j** as a white solid, 58.3 mg, 63% yield, m.p. 130-132 °C; ¹H NMR (500 MHz, CDCl₃) δ: 7.37-7.32 (m, 6H), 7.14 (d, *J* = 7.1 Hz, 1H), 7.09 (t, *J* = 7.3 Hz, 2H), 6.83 (t, *J* = 8.5 Hz, 2H), 6.67-6.57 (m, 2H), 6.55 (dd, *J*₁ = 8.3 Hz, *J*₂ = 5.3 Hz, 2H), 5.99 (q, *J* = 2.0 Hz, 1H), 5.26 (dd, *J*₁ = 12.2 Hz, *J*₂ = 9.8 Hz, 1H), 5.06 (dd, *J*₁ = 12.1 Hz, *J*₂ = 8.5 Hz, 1H), 4.93 (dd, *J*₁ = 12.2 Hz, *J*₂ = 6.7 Hz, 1H), 4.77 (t, *J* = 7.8 Hz, 1H), 4.62 (dd, *J*₁ = 9.7 Hz, *J*₂ = 6.7 Hz, 1H), 3.78-3.74 (m, 2H), 2.79 (d, *J* = 7.4 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃) δ: 162.5 (d, *J*_{C-F} = 248.2 Hz), 137.3, 137.2, 136.1, 132.3 (d, *J*_{C-F} = 2.5 Hz), 131.6 (d, *J*_{C-F} = 7.5 Hz), 130.7, 129.6, 128.6, 128.5, 128.3, 128.3, 128.1, 128.0, 115.3 (d, *J*_{C-F}


= 21.3 Hz), 79.0, 73.2, 49.0, 47.9, 47.6. ν_{\max} (neat, cm^{-1}): 3509, 2918, 1602, 1546, 1506, 1454, 1374, 1331, 1275, 1222, 1158, 1059. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{22}\text{FN}_2\text{O}_5$ ($[\text{M}-\text{H}]^-$): 461.1518; found: 461.1519. Enantiomeric excess of **4j** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 15.0 min, major enantiomer: t_R = 44.0 min.

(1'*R*,2'*S*,3'*S*,4'*S*)-4-Chloro-3'-nitro-5'-[(*R*)-2-nitro-1-phenylethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4k)




The crude material was purified by flash column chromatography using hexanes/EtOAc (95:5) as an eluent to get **4k** as a pale yellow solid, 58.3 mg, 61% yield, m.p. 135-137 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.38-7.32 (m, 6H), 7.15-7.10 (m, 6H), 6.60 (br, 2H), 6.51 (d, J = 8.1 Hz, 2H), 5.96 (d, J = 2.9 Hz, 1H), 5.26 (dd, J_1 = 12.2 Hz, J_2 = 9.8 Hz, 1H), 5.05 (dd, J_1 = 12.3 Hz, J_2 = 8.4 Hz, 1H), 4.92 (dd, J_1 = 12.2 Hz, J_2 = 6.7 Hz, 1H), 4.77 (t, J = 7.6 Hz, 1H), 4.61 (dd, J_1 = 9.9 Hz, J_2 = 6.7 Hz, 1H), 3.80-3.74 (m, 2H), 2.80 (d, J = 7.4 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ : 137.6, 137.1, 136.0, 135.1, 134.0, 131.4, 130.4, 129.6, 128.7, 128.6, 128.5, 128.3, 128.3, 128.1, 128.0, 90.4, 79.0, 73.2, 48.9, 48.0, 47.5. ν_{\max} (neat, cm^{-1}): 3523, 3029, 1547, 1489, 1454, 1374, 1274, 1091, 1013. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{ClN}_2\text{O}_5$ ($[\text{M}+\text{Na}]^+$): 501.1188; found: 501.1172. Enantiomeric excess of **4k** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 15.7 min, major enantiomer: t_R = 49.3 min.

(1'*R*,2'*S*,3'*S*,4'*S*)-4-Bromo-3'-nitro-5'-[(*R*)-2-nitro-1-phenylethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4l)



The crude material was purified by flash column chromatography using hexanes/EtOAc (95:5) as an eluent to get **4l** as a pale yellow solid, 64.9 mg, 62% yield, m.p. 140-142 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.41-7.30 (m, 7H), 7.27-7.25 (m, 4H), 7.18-7.08 (m, 4H), 6.60 (br, 2H), 6.45 (d, J = 8.0 Hz, 2H), 5.96 (d, J = 3.1 Hz, 1H), 5.26 (dd, J_1 = 12.2 Hz, J_2 = 9.9 Hz, 1H), 5.05 (dd, J_1 = 12.1 Hz, J_2 = 8.4 Hz, 1H), 4.92 (dd, J_1 = 12.2 Hz, J_2 = 6.7 Hz, 1H), 4.77 (t, J = 7.9 Hz, 1H), 4.61 (dd, J_1 = 9.9 Hz, J_2 = 6.7 Hz, 1H), 3.79-3.73 (m, 2H), 2.75 (d, J = 7.4 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ : 137.62, 137.10, 135.96, 135.65, 131.78, 131.54, 130.35, 129.60, 128.67, 128.49, 128.32, 128.29, 128.15, 127.98, 122.14, 90.34, 78.96, 73.21, 48.91, 48.08, 47.44. ν_{max} (neat, cm^{-1}): 2522, 2360, 2340, 2159, 2016, 1868, 1699, 1683, 1652, 1558, 1540, 1456, 1418, 1072. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{23}\text{BrN}_2\text{O}_5\text{Na}$ ($[\text{M}+\text{Na}]^+$): 545.0683; found: 545.0663. Enantiomeric excess of **4l** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 16.7 min, major enantiomer: t_R = 50.9 min.


(1'R,2'S,3'S,4'S)-4''-Bromo-5'-[(R)-1-(4-bromophenyl)-2-nitroethyl]-4-methoxy-3'-nitro-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-ol (4m**)**



The crude material was purified by flash column chromatography using hexanes/EtOAc (95:5) as an eluent to get **4m** as a white solid, 82.2 mg, 65% yield, m.p. 135-137 °C; ^1H NMR (500 MHz, CDCl_3) δ : 7.51 (d, J = 8.4 Hz, 2H), 7.25-7.21 (m, 6H), 6.71 (d, J = 8.8 Hz, 2H), 6.50 (d, J = 8.2 Hz, 2H), 6.45 (br, 2H), 5.97 (d, J = 3.9 Hz, 1H), 5.18 (dd, J_1 = 12.4 Hz, J_2 = 9.5 Hz, 1H), 5.02 (dd, J_1 = 12.5 Hz, J_2 = 8.4 Hz, 1H), 4.90 (dd, J_1 = 12.4 Hz, J_2 = 7.1 Hz, 1H), 4.74 (t, J = 6.9 Hz, 1H), 4.57 (dd, J_1 = 9.4 Hz, J_2 = 7.1 Hz, 1H), 3.78 (s, 3H), 3.72-3.65 (m, 2H), 2.75 (d, J = 7.2 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ : 159.6, 136.3, 136.3, 135.3, 132.7, 131.7, 131.3, 131.2, 130.2, 129.8, 127.8, 122.1, 114.1, 90.5, 78.7, 73.1, 55.6, 48.3, 47.6, 47.4. ν_{max} (neat, cm^{-1}): 3420, 2918, 2849, 1703, 1608, 1548, 1508, 1488, 1462, 1373, 1248, 1176, 1112, 1073. HRMS (ESI) m/z calcd for $\text{C}_{27}\text{H}_{23}\text{Br}_2\text{N}_2\text{O}_6$ ($[\text{M}-\text{H}]^-$): 628.9928; found: 628.9925.


Enantiomeric excess of **4m** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 16.0 min, major enantiomer: t_R = 55.5 min.

(1'*R*,2'*S*,3'*S*,4'*S*)-3'-Nitro-5'-[(*R*)-2-nitro-1-phenylethyl]-1',2',3',4'-tetrahydro-[1,1':2',1''-terphenyl]-4'-yl acetate (6)



The crude material was purified by flash column chromatography using hexanes/EtOAc (93:7) as an eluent to get **6** as a white solid, 38.7 mg, 80% yield, m.p. 181-183 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.40 (t, J = 7.4 Hz, 2H), 7.36 – 7.31 (m, 1H), 7.29 (d, J = 7.1 Hz, 2H), 7.23 (d, J = 7.3 Hz, 1H), 7.18 (t, J = 10.0 Hz, 2H), 7.13 (t, J = 7.4 Hz, 1H), 7.06 (t, J = 7.5 Hz, 2H), 6.68 (d, J = 7.1 Hz, 2H), 6.59 (br, 2H), 6.34 (d, J = 8.4 Hz, 1H), 6.08 (d, J = 5.7 Hz, 1H), 5.23 (dd, J_1 = 13.0 Hz, J_2 = 8.4 Hz, 1H), 4.87 (dd, J_1 = 13.4 Hz, J_2 = 8.8 Hz, 1H), 4.68 (dd, J_1 = 13.4 Hz, J_2 = 7.6 Hz, 1H), 4.43 (t, J = 8.2 Hz, 1H), 3.94 (dd, J_1 = 13.0 Hz, J_2 = 5.8 Hz, 1H), 3.85 (t, J = 5.7 Hz, 1H), 1.84 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 170.4, 137.4, 136.5, 135.8, 134.3, 131.0, 130.3, 129.6, 128.6, 128.5, 128.4, 128.1, 128.0, 87.3, 78.5, 73.8, 48.4, 47.8, 46.0, 20.7. ν_{max} (neat, cm^{-1}): 3028, 1739, 1547, 1491, 1453, 1427, 1368, 1271, 1209, 1087, 1015. HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{30}\text{N}_3\text{O}_6$ ($[\text{M}+\text{NH}_4]^+$): 504.2129; found: 504.2132. Enantiomeric excess of **6** was determined by chiral stationary phase HPLC analysis using a ChiralPak IB column (90:10 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 22.2 min, major enantiomer: t_R = 55.3 min.



(1'*R*,2'*S*,3'*S*)-3'-Nitro-5'-((*R*)-2-nitro-1-phenylethyl)-2',3'-dihydro-[1,1':2',1''-terphenyl]-4'(1'*H*)-one (7)





The crude material was purified by flash column chromatography using hexanes/EtOAc (92:8) as an eluent to get **7** as a white solid, 37.6 mg, 85 % yield, m.p. 125-127 °C, ^1H NMR (500 MHz, CDCl_3) δ 7.40-7.33 (m, 5H), 7.25 – 7.05 (m, 7H), 6.65 (d, J = 7.5 Hz, 2H), 6.56 (d, J = 7.6 Hz, 2H), 5.78 (d, J = 14.1 Hz, 1H), 5.17 (dd, J_1 = 12.7 Hz, J_2 = 8.9 Hz, 1H), 4.92 (t, J = 8.0 Hz, 1H), 4.84 (dd, J_1 = 12.7 Hz, J_2 = 7.1 Hz, 1H), 4.41 (dd, J_1 = 14.1 Hz, J_2 = 5.6 Hz, 1H), 4.11 (t, J = 5.8 Hz, 1H). ^{13}C NMR (125 MHz, CDCl_3) δ 187.4, 148.9, 137.0, 136.9, 135.6, 133.2, 130.0, 129.7, 129.0, 128.9, 128.8, 128.7, 128.5, 128.3, 127.9, 90.4, 76.9, 48.8, 48.5, 44.5. ν_{max} (neat, cm^{-1}): 1689, 1551, 1493, 1453, 1374, 1205, 1085, 1032, 918, 789, 766, 747. HRMS (ESI) m/z calcd for $\text{C}_{26}\text{H}_{26}\text{N}_3\text{O}_5$ ($[\text{M}+\text{NH}_4]^+$): 460.1867; found: 460.1871. Enantiomeric excess of **7** was determined by chiral stationary phase HPLC analysis using a ChiralPak IC column (70:30 hexanes/*i*-PrOH at 1.0 mL/min, λ = 220 nm), minor enantiomer: t_R = 25.6 min, major enantiomer: t_R = 37.3 min.

Additional References



12. a) Schönberger, M.; Trauner, D. *Angew. Chem., Int. Ed.* **2014**, *53*, 3264-3267. b) Reddy, B. V. S.; Sundar, C. S.; Reddy, M. R.; Reddy, C. S.; Sridhar B. *Synthesis* **2015**, *47*, 1117-1122.
13. a) Black, P.-J.; Gerta, C.-K.; Edwards, M. G.; Slatford, P. A.; Whittlesey, M. K.; Williams, J. M. J. *Org. Biomol. Chem.* **2006**, *4*, 116-125. b) Vo, Q. V.; Trenerry, C.; Rochfort, S.; Wadeson, J.; Leyton, C.; Hughes, A. B. *Bioorg. Med. Chem.* **2013**, *21*, 5945–5954.
14. a) Vakulya, B.; Varga, S.; Csámpai, A.; Soós, T. *Org. Lett.* **2005**, *7*, 1967-1969; b) Liu, Y.; Sun, B.; Wang, B.; Wakem, M.; Deng, L.; *J. Am. Chem. Soc.* **2009**, *131*, 418-419; c) Han, X.; Zhong, F.; Lua, Y. *Adv. Synth. Catal.* **2010**, *352*, 2778-2782, d) Yang, W.; Du, D.-M. *Org. Lett.* **2010**, *12*, 5450-5453; e) Li, X.; Deng, H.; Zhang, B.; Li, J.; Zhang, L.; S. Luo J.-P. Cheng, *Chem. Eur. J.* **2010**, *16*, 450; f) Hajra, S.; Jana, B. *Org. Lett.* **2017**, *19*, 4778-4781, g) Huang, H.; Konda, S.; Zhao, J. C. G. *Angew. Chem., Int. Ed.* **2016**, *55*, 2213-2216. h) Pozo, S. Del.; Vera, S.; Oiarbide, M.; Palomo, C. *J. Am. Chem. Soc.*, **2017**, *139*, 15308-15311. i) Tan, W.; Wei, J.; Jiang, X. *Org. Lett.* **2017**, *19*, 2166-2169.
15. Wenzel, A. G.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2002**, *124*, 12964–12965.







IV-DM-616D.1.fid

8.45 7.99 7.97 7.57 7.38 7.36 7.26 7.02 6.94 6.28 5.89 5.03 4.99 4.95 4.93 4.58 3.93 3.92 3.89 3.41 3.27 3.25 3.22 2.85 2.76 2.29 2.28 1.64 1.58 1.56 1.44 0.88




IV-DM-616D.2.fid


183.8 170.8 168.8 167.2 159.0 146.2 145.1 144.8 142.1 137.9 132.2 129.4 128.7 128.5 127.7 127.6 122.6 120.0 114.9 102.0 77.6 77.4 77.1 64.9 56.2 53.9 43.5 41.1 40.1 35.4 28.3 26.5





IV-DM-628.1.fid





IV-DM-628.2.fid




III-DM-369-0 P.1.40




III-DM-369-0 P.2.fid





IV-DM-669A.4.fid




IV-DM-669A.5.fid







1-SJ-569-P2.1.fid




1-SJ-569-P2-C13.1.fid






V-DM-714D2.1.fid






V-DM-714D2.2.fid














1-SJ-611-1.1.fid




1-SJ-611-1-C13.1.fid





1-SJ-614-PP-2.fid




1-SJ-614-PP-C13.1.fid










V-DM-751D.1.fid



V-DM-751D.2.fid








==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : III-DM-348P IC 10%.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 8/9/2018 6:13:54 PM
Data Processed : 8/9/2018 7:17:27 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	17.378	11766103	240670	26.003	37.145
2	19.677	5271434	99123	11.650	15.280
3	27.344	5516646	80894	12.193	13.468
4	33.708	5325206	64786	11.769	9.987
5	46.251	4964603	48121	10.973	7.418
6	48.628	12405483	114842	27.416	17.703
Total		45248465	648726	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : IV-DM-602.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 8/25/2018 4:58:04 PM
Data Processed : 8/25/2018 5:58:07 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	18.052	194273	4598	0.646	1.631
2	50.002	29867160	277344	99.354	98.369
Total		30061434	281943	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
 Sample Name :
 Sample ID :
 Vial # :
 Injection Volume : 1 uL
 Data File Name : IV-DM-894P IB 10%.lcd
 Method File Name : ChiralPak IB-10%-1.0 mL-220nm.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/4/2018 11:13:08 AM
 Data Processed : 10/4/2018 4:20:22 PM

<Chromatogram>




PeakTable						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	19.534	587153	8555	8.254	5.722	
2	20.647	3263077	68319	45.869	45.693	
3	22.973	3263743	72642	45.878	48.585	
Total		7113973	149517	100.000	100.000	

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
 Sample Name :
 Sample ID :
 Vial # :
 Injection Volume : 1 uL
 Data File Name : IV-DM-869A IB 10%.lcd
 Method File Name : ChiralPak IB-10%-1.0 mL-220nm.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/4/2018 12:55:44 PM
 Data Processed : 10/4/2018 2:35:47 PM

<Chromatogram>




PeakTable						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	21.126	315315	5938	0.708	0.860	
2	22.919	31606341	684760	99.292	99.140	
Total		31831457	690697	100.000	100.000	

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
 Sample Name :
 Sample ID :
 Vial # :
 Injection Volume : 1 uL
 Data File Name : V-DM-711 IC 10%.lcl
 Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
 Batch File Name :
 Report File Name : Default.lor
 Data Acquired : 10/8/2018 3:46:36 PM
 Data Processed : 10/8/2018 4:46:39 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.246	11963015	271375	50.522	63.019
2	32.258	11715869	159250	49.478	36.981
Total		23678884	430625	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
 Sample Name :
 Sample ID :
 Vial # :
 Injection Volume : 1 uL
 Data File Name : IV-DM-671 4F CHI.lcl
 Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
 Batch File Name :
 Report File Name : Default.lor
 Data Acquired : 10/8/2018 5:03:51 PM
 Data Processed : 10/8/2018 6:03:55 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	10.367	898940	19002	0.823	1.393
2	31.828	108278107	1344869	99.177	98.607
Total		109177047	1363871	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
 Sample Name :
 Sample ID :
 Vial # :
 Injection Volume : 1 uL
 Data File Name : 1-SJ-594.lcd
 Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/10/2018 6:17:54 PM
 Data Processed : 10/10/2018 7:17:58 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.033	34291318	1068470	22.350	31.549
2	12.043	44135861	1240781	28.767	36.637
3	23.900	39627253	638539	25.828	18.834
4	33.257	35371072	438018	23.054	12.980
Total		153425508	3386708	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
 Sample Name :
 Sample ID :
 Vial # :
 Injection Volume : 1 uL
 Data File Name : 1-SJ-569.lcd
 Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/10/2018 1:06:15 PM
 Data Processed : 10/10/2018 2:26:37 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	11.088	793819	29298	0.488	1.500
2	32.514	161842480	1923341	99.512	98.500
Total		162636299	1952637	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-715 IC 7.5%.lcd
Method File Name : ChiralPak IC-7.5%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/9/2018 9:12:53 AM
Data Processed : 10/9/2018 10:48:51 AM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.742	3796840	80413	16.223	23.484
2	18.303	7538566	150689	32.208	43.970
3	40.275	7541959	70688	32.223	20.626
4	42.642	693898	11182	4.204	3.293
5	53.348	3544348	29757	15.143	6.677
Total		23405612	342710	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : IV-DM-S573.lcd
Method File Name : ChiralPak IC-7.5%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/9/2018 10:45:37 AM
Data Processed : 10/9/2018 12:08:29 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.163	192709	3208	0.454	0.961
2	53.393	42210372	330623	99.546	99.039
Total		42403081	333831	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-735.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/18/2018 4:30:30 PM
Data Processed : 10/18/2018 5:23:41 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.026	9280395	189305	50.699	67.958
2	41.072	9024612	89256	49.301	32.042
Total		18305007	278561	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-734.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/18/2018 3:28:32 PM
Data Processed : 10/18/2018 4:19:41 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.667	588389	8374	0.833	1.237
2	40.473	70067258	668486	99.167	98.763
Total		70655647	676860	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : IV-DM-712 R IC 5%.lcd
Method File Name : ChiralPak IC-5%-1 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/8/2018 4:23:30 PM
Data Processed : 10/8/2018 11:07:19 AM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	32.766	6089510	66851	19.081	26.172
2	36.985	10006213	105190	31.354	41.182
3	68.905	10067276	51993	31.545	20.356
4	86.172	5751168	31391	18.031	12.290
Total		31914167	255425	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : IV-DM-673 IC 5%.lcd
Method File Name : ChiralPak IC-5%-1 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/8/2018 9:50:01 AM
Data Processed : 10/8/2018 4:24:07 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	32.327	353945	3596	1.130	2.160
2	85.317	30959935	162916	98.870	97.840
Total		31313880	166512	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-717 IC 10%.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/9/2018 3:04:32 PM
Data Processed : 10/9/2018 5:29:26 PM

<Chromatogram>




Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.529	3883238	94045	42.925	61.988
2	44.975	344279	4239	3.585	2.793
3	46.448	3974710	41527	43.936	27.363
4	48.890	824311	11954	9.554	7.857
Total		9046537	151765	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : IV-DM-677 IC 10%.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/9/2018 4:36:37 PM
Data Processed : 10/18/2018 7:14:53 PM

<Chromatogram>




Peak#	Ret. Time	Area	Height	Area %	Height %
1	19.491	191888	4634	0.765	1.815
2	46.223	24900111	250692	99.235	98.185
Total		25092000	255326	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-725 RAC.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Report File Name : Default.lcr
Data Acquired : 10/15/2018 4:27:21 PM
Data Processed : 10/15/2018 5:57:24 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	23.319	8833793	151019	47.578	71.320
2	68.672	917401	6473	4.930	3.057
3	73.031	8837953	54255	47.493	25.623
Total		18609147	211748	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-724 IC 10%.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Report File Name : Default.lcr
Data Acquired : 10/15/2018 6:01:26 PM
Data Processed : 10/15/2018 7:31:29 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	23.416	679467	12187	0.647	1.981
2	71.720	104407112	608993	99.353	98.038
Total		105086579	621181	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : 1-SJ-618-10%.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/20/2018 2:57:47 PM
Data Processed : 10/20/2018 3:50:05 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	14.961	42474210	1174565	59.477	81.936
2	44.911	28938325	258955	40.523	18.064
Total		71412534	1433521	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : 1-SJ-611.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/20/2018 2:01:49 PM
Data Processed : 10/20/2018 2:55:55 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.033	3229125	90107	2.487	7.223
2	44.007	126637979	1157355	97.513	92.777
Total		129857105	1247462	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : 1-SJ-804.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/28/2018 12:27:13 PM
Data Processed : 10/28/2018 2:47:20 PM

<Chromatogram>




PeakTable						
Peak#	Ret. Time	Area	Height	Area %	Height %	
1	14.774	30818795	944832	18.027	29.356	
2	15.756	34035482	911980	19.908	28.335	
3	23.698	21527587	373322	12.592	11.599	
4	27.198	11950783	184651	6.990	5.737	
5	29.690	36775739	487298	21.511	15.140	
6	49.982	35853756	316460	20.972	9.832	
Total		170962142	3218542	100.000	100.000	

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : 1-SJ-814.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 10/28/2018 1:45:10 PM
Data Processed : 10/28/2018 2:50:11 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.788	882003	24028	0.776	2.480
2	49.304	112808883	945004	99.224	97.520
Total		113690887	969032	100.000	100.000

==== Shimadzu LCsolution Analysis Report =====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : 1-SJ-646.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Date Acquired : 11/12/2018 1:26:01 PM
Date Processed : 11/12/2018 4:00:17 PM

<Chromatogram>




Peak#	Ret. Time	Area	Height	Area %	Height %
1	15.083	190853.90	520094	12.120	21.126
2	16.606	18947981	456215	12.053	18.531
3	24.073	55544601	546321	21.303	22.191
4	27.624	7537926	90094	4.757	3.660
5	30.973	19496274	240057	12.381	9.751
6	36.386	53211221	42431	2.159	1.924
7	38.700	37952119	80365	2.408	3.264
8	39.976	55048994	526666	20.985	15.260
9	52.520	18696358	159612	11.873	6.483
Total		157466825	2461855	100.000	100.000

==== Shimadzu LCsolution Analysis Report =====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : 1-SJ-644.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Date Acquired : 11/12/2018 2:53:00 PM
Date Processed : 11/12/2018 4:04:33 PM

<Chromatogram>




Peak#	Ret. Time	Area	Height	Area %	Height %
1	16.718	1946296	43136	0.701	2.127
2	50.905	275893558	1985038	99.299	97.873
Total		277839854	2026174	100.000	100.000

==== Shimadzu LCsolution Analysis Report =====

Acquired by : Admin
Sample Name :
Sample ID :
Vial# :
Injection Volume : 1 µL
Data File Name : V-DM-752 Rac R.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Date Acquired : 10/24/2018 1:11:25 PM
Date Processed : 10/24/2018 2:16:27 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area%	Height%
1	16.002	14240049	310023	47.513	74.155
2	56.114	15718246	108082	52.487	25.844
Total		29958295	4182105	100.000	100.000

==== Shimadzu LCsolution Analysis Report =====

Acquired by : Admin
Sample Name :
Sample ID :
Vial# :
Injection Volume : 1 µL
Data File Name : V-DM-751 R.lcd
Method File Name : ChiralPak IC-10%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Date Acquired : 10/23/2018 4:50:08 PM
Date Processed : 10/23/2018 5:55:11 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area%	Height%
1	16.026	153001	3586	1.245	3.821
2	56.066	12329916	90209	98.755	96.177
Total		12330017	93795	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-868 RAC.lcd
Method File Name : ChiralPak ID-15.0%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 12/19/2018 4:38:24 PM
Data Processed : 12/19/2018 5:45:54 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.364	3954339	66365	49.052	68.549
2	55.658	3068489	30450	50.948	31.451
Total		6022827	96815	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-738 RE.lcd
Method File Name : ChiralPak ID-15.0%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 12/19/2018 3:14:12 PM
Data Processed : 12/19/2018 4:21:54 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	22.160	15855045	356185	99.816	99.907
2	55.354	29215	333	0.184	0.093
Total		15884261	356518	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-876 RAC IC 30%.lcd
Method File Name : ChiralPak IC-30%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 12/31/2018 2:29:46 PM
Data Processed : 12/31/2018 6:10:59 PM

<Chromatogram>




PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	25.269	1023779	18956	37.358	47.113
2	35.475	676890	8835	24.700	21.957
3	36.988	1039798	12446	37.942	30.931
Total		2740467	40236	100.000	100.000

==== Shimadzu LCsolution Analysis Report ====

Acquired by : Admin
Sample Name :
Sample ID :
Vial # :
Injection Volume : 1 uL
Data File Name : V-DM-875D IC 30%.lcd
Method File Name : ChiralPak IC-30%-1.0 mL-220nm.lcm
Batch File Name :
Report File Name : Default.lcr
Data Acquired : 12/31/2018 4:14:49 PM
Data Processed : 12/31/2018 6:05:23 PM

<Chromatogram>



PeakTable					
Peak#	Ret. Time	Area	Height	Area %	Height %
1	25.633	91003	1830	0.460	0.798
2	37.300	19679493	226138	99.540	99.202
Total		19770494	227968	100.000	100.000